Prof Solange Peters speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the MYSTIC trial that aims to evaluate the opportunity of administering front-line immunotherapy in patients with metastatic NSCLC.

This three-arm randomised trial consisted of administering durvalumab, with or without tremelimumab versus platinum-based chemotherapy.

Prof Peters discusses why the primary endpoint did not reach statistical significance, despite achieving a clinically meaningful result that supported the use of durvalumab compared to chemotherapy.

Prof Peters also explains the role of the 'tumour mutational burden' as a clinical biomarker for this disease type in the future.